Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

New Plasmids Developed for Real-Time Monitoring of Key Intracellular Molecules

By BiotechDaily International staff writers
Posted on 28 Mar 2013
Print article
New plasmids are now available for real-time assays enabling cell biology as well as drug discovery researchers to visualize and study the in vivo action of target molecules involved in key regulatory cell processes.

ChromoTek GmbH (Munich, Germany) offers the new nanobody based “Chromobody Plasmids” to visualize and measure the action of candidate drugs or other substances of interest on important regulatory processes in living cells. Presently, four plasmids are available: for analyzing the cell cycle, apoptosis, DNA methylation, and cytoskeleton dynamics. A major advantage of the new Chromobody plasmids compared to Chromobody cell lines already available is that researchers can now monitor cellular pathways in their own cells or cell lines simply by carrying out a transfection. Unlike conventional, end-point assays, the Chromobody plasmids allow the fate of endogeneous target proteins to be followed over time, also visually in a movie-like format. Additionally, as the fluorescently labeled intracellular antibodies expressed from these plasmids do not interfere with the activity of their targets, they are extremely useful for high-content screening.

The new product format is equally suitable for academic researchers who want to decipher cellular pathways and for biotech and pharma researchers seeking to enhance their drug discovery and high-throughput screening capabilities. “We are glad to be able to offer our customers a new product format that gives them greater flexibility both in basic cell biology research and in drug discovery and validation processes,” stated Marion Jung, Managing Director of ChromoTek. Researchers who would like to try the Chromobody technology for their own applications can now choose between three options: license a cell line; order assay-ready frozen instant cells via ChromoTek or via CCS (Cell Culture Service, now part of Evotec AG); or purchase a Chromobody plasmid.

Related Links:

ChromoTek



Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.